Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Scientists probe new theories on whether AstraZeneca shot linked to blood clots

03/19/2021 | 08:15pm EDT

CHICAGO, March 19 (Reuters) - Scientists are exploring several possibilities that might explain at least 18 reports of extremely rare blood clots in the brain that occurred in individuals in the days and weeks after receiving the AstraZeneca COVID-19 vaccine.

European investigators have put forward one theory that the vaccine triggers an unusual antibody in some rare cases; others are trying to understand whether the cases are linked with birth control pills.

But many scientists say there is no definitive evidence and it is not clear whether or why AstraZeneca's vaccine would cause an issue not shared by other vaccines that target a similar part of the coronavirus.

Most of the rare blood clots have been seen in women and most cases have been reported in Europe. Two cases have been reported in India.

The European Medicines Agency said a preliminary review suggests the vaccine is not associated with an increase in the overall risk of blood clots. But it did not rule out an association with rare cases of blood clots in vessels draining the blood from the brain known as cerebral venous sinus thrombosis (CVST).

Researchers in Germany and Norway, where some of the cases have been reported, this week hypothesized that the vaccine could be triggering an immune response in which the body produces antibodies that could result in blood clots.

Professor Paal Andre Holme of Norway's Oslo University Hospital, which treated three healthcare workers with severe blood clots after they received the AstraZeneca vaccine, told a news conference on Thursday that "we've made discoveries" that could "explain the clinical progression of our patients."

Holme warned that the findings were preliminary. "This is only the beginning of all the research that is being done," he said. He did not release any data supporting his hypothesis.

A team of German researchers at Greifswald University Clinic on Friday said they came to a similar conclusion. If proven correct, there may be a way to treat the condition, the scientists said.

EMA researchers on Thursday said they are undertaking several investigations to determine whether the rare blood clots might be linked with the vaccine, or occurring by chance. They noted that many of the events occurred in younger women.

CVST, though rare, has been associated with pregnancy and the use of oral contraceptives. "That's one of the things that we will be further investigating in the near future," said Sabine Straus, chair of EMA's safety committee.

EMA also intends to investigate whether those who developed the condition had been infected previously or at the time of the vaccine with COVID-19, which can cause blood clots.

Several U.S. vaccine experts remain cautious about the antibody hypothesis and said the high level of publicity of the events could be causing more clinicians to report the condition than normal, which would make it appear that the events are related to the vaccine.

AstraZeneca's vaccine has received emergency use authorization in 70 countries, but it has not yet been approved in the United States.

The U.S. experts also question why such events would occur only at increased rates with the AstraZeneca vaccine and not the vaccines by Pfizer Inc and BioNTech SE, Moderna Inc, Johnson & Johnson and Russia's Sputnik V vaccine - all of which are intended to produce antibodies aimed at the "spike" portion of the coronavirus that it uses to enter cells.

Like the J&J and the Sputnik vaccine, AstraZeneca's uses a non-replicating cold virus known as an adenovirus to deliver spike proteins into cells and produce an immune response.

"We'll have to see when (German and Norwegian scientists) submit a peer-reviewed publication and the scientific community can review it," said Dr. Peter Hotez, a vaccine researcher at Baylor College of Medicine in Houston. "There's no reason why the AstraZeneca vaccine would do this whereas the others, including the adenovirus-based COVID-19 vaccines, wouldn't." (Reporting by Julie Steenhuysen; additional reporting by Terje Solsvik in Oslo; editing by Peter Henderson and Leslie Adler)

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.07% 8406 Delayed Quote.14.90%
BIONTECH SE -0.75% 227.79 Delayed Quote.179.43%
MODERNA, INC. 3.82% 220.14 Delayed Quote.110.72%
PFIZER, INC. 0.36% 39.19 Delayed Quote.6.47%
All news about ASTRAZENECA PLC
05:44aSanofi-Regeneron Secures Two New Cancer Nods for Libtayo Amid Rising Competit..
06/24ASTRAZENECA  : Japan to give 6 mln doses of vaccines to Taiwan, 5 SE Asia nation..
06/24ASTRAZENECA  : Japan to give 1 mln doses of vaccine each to Taiwan, Vietnam, say..
06/24THE LATEST : Thousands of vaccines set to expire in Romania
06/24WH Smith moves to pacify investors angered over executive pay
06/24ASTRAZENECA  : Swiss health ministry data shows vaccinated people seldom hit by ..
06/24ASTRAZENECA  : EU slightly cuts estimates for vaccine deliveries this year
06/24WHO estimates COVID-19 boosters needed yearly for most vulnerable
06/24ASTRAZENECA  : 30 Covid-19 Deaths in Kenya as 622 New Cases Posted
06/24DOW JONES FXCM DOLLAR INDEX  : NAB on Updated Australia's COVID-19 Vaccine Suppl..
More news
Financials (USD)
Sales 2021 30 988 M - -
Net income 2021 4 559 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 36,9x
Yield 2021 2,44%
Capitalization 154 B 154 B -
EV / Sales 2021 5,31x
EV / Sales 2022 4,58x
Nbr of Employees 76 100
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 117,09 $
Average target price 132,44 $
Spread / Average Target 13,1%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC14.90%153 571
JOHNSON & JOHNSON3.81%428 269
ROCHE HOLDING AG11.02%323 588
PFIZER, INC.6.47%218 590
NOVARTIS AG1.71%207 904
ABBVIE INC.7.08%202 656